The SGLT2 inhibitor empagliflozin met the primary outcome measure in reducing risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes, as demonstrated by the results of the randomized, double-blind phase III EMPEROR-Reduced study. In addition, the safety profile was consistent with the known safety profile of empagliflozin. Treatment consisted of daily intake of 10 mg empagliflozin in addition to standard treatment by HFrEF patients (n=3730), and was compared with placebo.
The EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR)-Reduced study is part of the EMPOWER program, a broad study examining the effect of empagliflozin on patients with cardiometabolic and renal diseases. Full results of EMPEROR-Reduced will be presented on August 29, 2020 during the ESC digital conference.